Apical sodium-dependent bile acid transporter inhibitors have revolutionized care for children with genetic cholestasis. This Clinical Outlook discusses how this new class of drugs came into clinical practice and how they might benefit transplant-free survival for a multitude of indications.
- Tamir Diamond
- Binita M. Kamath
